Zomedica Pharmaceuticals Corp
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital sign… Read more
Market Cap & Net Worth: Zomedica Pharmaceuticals Corp (ZOM)
Zomedica Pharmaceuticals Corp (NYSE MKT:ZOM) has a market capitalization of $53.90 Million ($53.90 Million) as of March 18, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #20985 globally and #7568 in its home market, demonstrating a 3.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zomedica Pharmaceuticals Corp's stock price $0.06 by its total outstanding shares 979950016 (979.95 Million).
Zomedica Pharmaceuticals Corp Market Cap History: 2016 to 2025
Zomedica Pharmaceuticals Corp's market capitalization history from 2016 to 2025. Data shows change from $1.01 Billion to $53.90 Million (-26.59% CAGR).
Zomedica Pharmaceuticals Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zomedica Pharmaceuticals Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.31x
Zomedica Pharmaceuticals Corp's market cap is 4.31 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $225.98 Million | $14.12K | -$16.92 Million | 15999.47x | N/A |
| 2021 | $300.35 Million | $4.13 Million | -$18.38 Million | 72.67x | N/A |
| 2022 | $159.73 Million | $18.93 Million | -$17.02 Million | 8.44x | N/A |
| 2023 | $196.19 Million | $25.19 Million | -$34.53 Million | 7.79x | N/A |
| 2024 | $117.59 Million | $27.29 Million | -$46.98 Million | 4.31x | N/A |
Competitor Companies of ZOM by Market Capitalization
Companies near Zomedica Pharmaceuticals Corp in the global market cap rankings as of March 18, 2026.
Key companies related to Zomedica Pharmaceuticals Corp by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Zomedica Pharmaceuticals Corp Historical Marketcap From 2016 to 2025
Between 2016 and today, Zomedica Pharmaceuticals Corp's market cap moved from $1.01 Billion to $ 53.90 Million, with a yearly change of -26.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $53.90 Million | -54.17% |
| 2024 | $117.59 Million | -40.06% |
| 2023 | $196.19 Million | +22.82% |
| 2022 | $159.73 Million | -46.82% |
| 2021 | $300.35 Million | +32.91% |
| 2020 | $225.98 Million | -30.33% |
| 2019 | $324.36 Million | -73.09% |
| 2018 | $1.21 Billion | -37.79% |
| 2017 | $1.94 Billion | +91.71% |
| 2016 | $1.01 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Zomedica Pharmaceuticals Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.90 Million USD |
| MoneyControl | $53.90 Million USD |
| MarketWatch | $53.90 Million USD |
| marketcap.company | $53.90 Million USD |
| Reuters | $53.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.